Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Basal (18)F-FDG PET/CT as a predictive biomarker of tumor response for neoadjuvant therapy in breast cancer.

Revista espanola de medicina nuclear e imagen molecular - 1 Jan 2000

García Vicente A M, Soriano Castrejón A, Pruneda-González R E, Fernández Calvo G, Muñoz Sánchez M M, Álvarez Cabellos R, Espinosa Aunión R, Relea Calatayud F

Abstract excerpt

PURPOSE: To explore the relation between tumor kinetic assessed by (18)F-FDG PET and final neoadjuvant chemotherapy (NC) response within a molecular phenotype perspective. MATERIAL AND METHODS: Prospective study included 144 women with breast cancer. All patients underwent a dual-time point (18)F-FDG PET/CT previous to NC. The retention index (RI), between SUV-1 and SUV-2 was calculated. Molecular subtypes were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoadjuvant Therapy

Share to Phenotype

Share to Positron Emission Tomography Computed Tomography

Source

Identifiers

PMID: 26521995
DOI: 10.1016/j.remn.2015.09.001

Genes

TRG

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Basal (18)F-FDG PET/CT as a predictive biomarker of tumor response for neoadjuvant therapy in breast cancer.PMID 26521995Read ↗

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy.Semantic proximity Read ↗

Glycolytic activity in breast cancer using 18F-FDG PET/CT as prognostic predictor: A molecular phenotype approach.Semantic proximity Read ↗

MRI phenotype of breast cancer: Kinetic assessment for molecular subtypes.Semantic proximity Read ↗

Breast Cancer Blood Flow and Metabolism on Dual-Acquisition 18F-FDG PET: Correlation with Tumor Phenotype and Neoadjuvant Chemotherapy Response.Semantic proximity Read ↗

Predicting Neoadjuvant Response of Breast Cancer at two 18F‑FDG PET/CT scanners with Radiomics model based on Combat Algorithm and Ratio FeaturesSemantic proximity Read ↗

Early Identification of Breast Cancer Patients Achieving Radiological Complete Response to NAC: A Clinicopathological and MRI-Based ApproachSemantic proximity Read ↗

Effect of breast cancer phenotype on diagnostic performance of MRI in the prediction to response to neoadjuvant treatment.Semantic proximity Read ↗

PET/CT Imaging for Monitoring Recurrence and Evaluating Response to Treatment in Breast Cancer.Semantic proximity Read ↗

Early 18F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.Semantic proximity Read ↗

Development of novel imaging biomarkers using positron emission tomography for characterization of malignant phenotype and response evaluationSemantic proximity Read ↗

Vascular characterisation of triple negative breast carcinomas using dynamic MRI.Semantic proximity Read ↗

Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.